Scarica l'app Stockscreener
62.56
1.94%
1.007
Precedente Chiudi:
$61.55
Aprire:
$61.81
Volume 24 ore:
1.45M
Relative Volume:
0.47
Capitalizzazione di mercato:
$3.43B
Reddito:
$14.34M
Utile/perdita netta:
$-199.00M
Rapporto P/E:
-15.96
EPS:
-3.92
Flusso di cassa netto:
$-183.51M
1 W Prestazione:
+18.60%
1M Prestazione:
+280.65%
6M Prestazione:
+602.69%
1 anno Prestazione:
+1,011%
Intervallo 1D:
$61.45
$63.57
Intervallo di 1 settimana:
$50.80
$65.12
Portata 52W:
$5.35
$65.12
Uniqure N V Stock (QURE) Company Profile
Nome
Uniqure N V
Settore
Industria
Telefono
1-339-970-7000
Indirizzo
PAASHEUVELWEG 25A, AMSTERDAM
Confronta QURE con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
QURE
Uniqure N V
|
62.54 | 3.79B | 14.34M | -199.00M | -183.51M | -3.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
472.79 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.13 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
801.26 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
331.45 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Uniqure N V Stock (QURE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-14 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-04-01 | Ripresa | Chardan Capital Markets | Buy |
| 2024-12-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-02-29 | Downgrade | Goldman | Buy → Neutral |
| 2023-12-19 | Downgrade | Mizuho | Buy → Neutral |
| 2022-03-17 | Aggiornamento | UBS | Neutral → Buy |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-05-21 | Iniziato | UBS | Neutral |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-04-01 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-24 | Iniziato | H.C. Wainwright | Buy |
| 2020-11-11 | Iniziato | Berenberg | Buy |
| 2020-11-09 | Iniziato | Jefferies | Buy |
| 2020-11-04 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-08-25 | Iniziato | Raymond James | Strong Buy |
| 2020-07-31 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2020-06-25 | Downgrade | Mizuho | Buy → Neutral |
| 2020-06-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-06-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2019-12-03 | Iniziato | Cowen | Outperform |
| 2019-12-03 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | Credit Suisse | Outperform |
| 2019-10-11 | Iniziato | Stifel | Buy |
| 2019-09-25 | Iniziato | Bernstein | Outperform |
| 2019-09-12 | Iniziato | Mizuho | Buy |
| 2019-07-30 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-07-08 | Reiterato | Cantor Fitzgerald | Overweight |
| 2019-04-12 | Iniziato | Piper Jaffray | Overweight |
| 2019-03-29 | Iniziato | Robert W. Baird | Outperform |
Mostra tutto
Uniqure N V Borsa (QURE) Ultime notizie
Using Bollinger Bands to evaluate uniQure N.V.Index Update & Technical Pattern Based Buy Signals - newser.com
Can uniQure N.V. stock hit analyst price targetsBull Run & Stepwise Swing Trade Plans - newser.com
Is uniQure N.V. stock trading at a premium valuationJuly 2025 Closing Moves & Weekly Top Gainers Alerts - newser.com
How institutional buying supports uniQure N.V. stockJuly 2025 Setups & Expert Curated Trade Setups - newser.com
Is uniQure N.V. stock a safe investment in uncertain marketsTrade Risk Report & Long-Term Safe Investment Plans - newser.com
uniQure NV Hits New 52-Week High of $61.79, Surging 1014.68% - Markets Mojo
uniQure N.V. (NASDAQ:QURE) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
uniQure N.V. (QURE) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Is uniQure’s Rally Justified After Positive Huntington’s Disease Therapy Data? - Yahoo Finance
Jim Cramer on uniQure: “This One Has Too Many Questions for Me Up Here” - MSN
Trend analysis for uniQure N.V. this week2025 Momentum Check & Expert Verified Movement Alerts - newser.com
Will uniQure N.V. see short term momentumBreakout Watch & Verified Technical Trade Signals - newser.com
Will uniQure N.V. (UQ1) stock beat value stocksDay Trade & AI Powered Market Trend Analysis - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for uniQure (NASDAQ:QURE) - MarketBeat
Is uniQure’s Stock Poised for a Comeback? - StocksToTrade
Price momentum metrics for uniQure N.V. explainedBreakout Watch & Technical Entry and Exit Tips - newser.com
Developing predictive dashboards with uniQure N.V. dataWeekly Trade Report & Verified Stock Trade Ideas - newser.com
Biopharma Financing Veers Toward Optimism, But Cell And Gene Therapies Left Behind - insights.citeline.com
uniQure: Further Upside Likely As The Opportunity Becomes Better Understood (QURE) - Seeking Alpha
uniQure NV Hits Day High with 9.47% Surge Amid Strong Intraday Performance - Markets Mojo
uniQure (NASDAQ:QURE) Sets New 12-Month HighTime to Buy? - MarketBeat
Uniqure NV stock hits 52-week high at 60.84 USD By Investing.com - Investing.com Nigeria
RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $65 - 富途牛牛
Uniqure NV stock hits 52-week high at 60.84 USD - Investing.com
United States Adeno-Associated Virus (AAV) Vectors - openPR.com
HC Wainwright Analysts Lift Earnings Estimates for uniQure - MarketBeat
UniQure’s Unexpected Surge: Analyzing QURE’s Performance - timothysykes.com
uniQure (NASDAQ:QURE) Shares Up 7.7% Following Analyst Upgrade - MarketBeat
HC Wainwright Issues Positive Forecast for uniQure Earnings - MarketBeat
uniQure’s Huntington’s gene therapy holds blockbuster potential, says analyst - The Pharma Letter
Why uniQure (QURE) Is Up After Strong AMT-130 Data and $475 Million in New Funding - Sahm
uniQure (NASDAQ:QURE) Price Target Raised to $110.00 at HC Wainwright - MarketBeat
HC Wainwright & Co. Maintains uniQure N.V. (QURE) Buy Recommendation - Nasdaq
uniQure stock price target raised to $110 from $70 at H.C. Wainwright - Investing.com
uniQure (QURE) Receives Boosted Price Target from HC Wainwright & Co. | QURE Stock News - GuruFocus
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $110 - 富途牛牛
Is uniQure N.V. (UQ1) stock nearing a technical breakout2025 Bull vs Bear & Consistent Return Investment Signals - newser.com
Is uniQure N.V. meeting your algorithmic filter criteriaJuly 2025 Catalysts & Smart Investment Allocation Insights - newser.com
Is uniQure N.V. showing signs of accumulation2025 Biggest Moves & Free Safe Capital Growth Stock Tips - newser.com
Is uniQure N.V. (UQ1) stock a top dividend aristocrat candidate2025 Institutional Moves & Weekly High Return Stock Forecasts - newser.com
Will uniQure N.V. bounce back from current supportEarnings Beat & Safe Entry Zone Identification - newser.com
uniQure N.V. stock retracement – recovery analysisDay Trade & Weekly Return Optimization Plans - newser.com
Measuring uniQure N.V.’s beta against major indices2025 Growth vs Value & Safe Entry Momentum Stock Tips - newser.com
QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop - MarketBeat
Morgan Lewis Advises UniQure in $345 Million Public Equity Offering – News - Morgan Lewis
Visual trend scoring systems applied to uniQure N.V.Quarterly Performance Summary & High Accuracy Swing Entry Alerts - newser.com
How to build a custom watchlist for uniQure N.V.Portfolio Profit Report & Growth Oriented Trade Recommendations - newser.com
Uniqure N V Azioni (QURE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Uniqure N V Azioni (QURE) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Kapusta Matthew C | CEO, Managing Director |
Sep 24 '25 |
Sale |
41.46 |
226,316 |
9,382,473 |
651,454 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 26 '25 |
Option Exercise |
5.37 |
15,000 |
80,550 |
232,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 24 '25 |
Option Exercise |
13.03 |
3,000 |
39,090 |
220,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 26 '25 |
Sale |
55.00 |
15,000 |
825,000 |
217,730 |
| KLEMT CHRISTIAN | Chief Financial Officer |
Sep 24 '25 |
Sale |
40.04 |
3,000 |
120,120 |
217,730 |
1.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):